Biotech · Private company
Secura Bio, Inc.
Track this companyFree. Adds Secura Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials103 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials10
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)PHASE1 · RECRUITING · started Aug 8, 2025ClinicalTrials.gov NCT07001384 · fetched Nov 12, 2026
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyEARLY_PHASE1 · COMPLETED · started Jan 13, 2022ClinicalTrials.gov NCT04890236 · fetched Nov 12, 2026
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyPHASE1 · COMPLETED · started Nov 18, 2021ClinicalTrials.gov NCT05065866 · fetched Nov 12, 2026
- Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCPHASE2 · COMPLETED · started Oct 14, 2021ClinicalTrials.gov NCT05057247 · fetched Nov 12, 2026
- Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaPHASE1_PHASE2 · TERMINATED · started Oct 6, 2021ClinicalTrials.gov NCT04688658 · fetched Nov 12, 2026
- Phase I Study of Marizomib + Panobinostat for Children With DIPGPHASE1 · TERMINATED · started Aug 10, 2020ClinicalTrials.gov NCT04341311 · fetched Nov 12, 2026
- A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRTPHASE2 · TERMINATED · started Jan 9, 2019ClinicalTrials.gov NCT04897880 · fetched Nov 12, 2026
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSPHASE1_PHASE2 · COMPLETED · started Jul 12, 2018ClinicalTrials.gov NCT03534323 · fetched Nov 12, 2026
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 27, 2014ClinicalTrials.gov NCT02158091 · fetched Nov 12, 2026
- Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseasePHASE1 · RECRUITING · started Nov 1, 2010ClinicalTrials.gov NCT01245179 · fetched Nov 12, 2026